中度风险患者的主要不良心脏事件发生率:既往冠心病是否有影响
本研究为HEART Pathway实施研究的二次分析,前瞻性中断时间序列研究纳入三个中心2013年11月至2016年1月因疑似急性冠脉综合征就诊的成人,排除急诊医生HEART Pathway评估为低风险者。中度风险定义为HEAR评分≥4分、肌钙蛋白阴性且心电图无缺血,按既往冠心病分层。4550例中24.8%为高风险、37.7%为中度风险;中度风险患者30天MACE发生率3.1%(53/1715,95%CI 2.3%-4.0%),既往冠心病者7.1%(36/508)显著高于无冠心病者1.4%(17/1207)(p<0.0001)。
要点
- 中度风险患者30天MACE率为3.1%(53/1715,95%CI 2.3%-4.0%),总体较低。
- 中度风险合并既往冠心病者30天MACE率7.1%(36/508,95%CI 5.1%-9.8%),显著高于无冠心病者的1.4%(17/1207,95%CI 0.9%-2.3%)(p<0.0001)。
- 无既往冠心病的的中度风险患者30天MACE阴性似然比为0.08(95%CI 0.05-0.12)。
- 中度风险定义为HEAR评分≥4分、肌钙蛋白阴性且心电图无缺血;高风险为肌钙蛋白升高或心电图缺血。
适用人群与场景
- 因疑似急性冠脉综合征就诊的成人,来自三个中心,2013年11月至2016年1月。
- 排除经急诊医生HEART Pathway评估为低风险的患者。
诊断标准与关键阈值
- 中度风险:HEAR评分≥4分、肌钙蛋白阴性且心电图无缺血。
- 高风险:肌钙蛋白升高或心电图缺血。
- 既往冠心病定义:心肌梗死、血运重建或冠状动脉狭窄≥70%。
研究设计与关键结果
- 研究类型:HEART Pathway实施研究的前瞻性中断时间序列研究的二次分析,纳入4550例患者。
- 4550例中高风险24.8%(1130/4550),中度风险37.7%(1715/4550)。
- 中度风险患者30天MACE率3.1%(53/1715;95%CI 2.3%-4.0%)。
- 中度风险患者中,既往冠心病者30天MACE率7.1%(36/508,95%CI 5.1%-9.8%),无既往冠心病者1.4%(17/1207,95%CI 0.9%-2.3%),差异有统计学意义(p<0.0001)。
- 无既往冠心病的中度风险患者30天MACE阴性似然比0.08(95%CI 0.05-0.12)。
证据类型、等级与局限
- 证据类型:前瞻性中断时间序列研究的二次分析。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,中度风险患者30天MACE率低,但既往冠心病者显著更高。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite negative troponins and nonischemic electrocardiograms (ECGs), patients at moderate risk for acute coronary syndrome (ACS) are frequently admitted. The objective of this study was to describe the major adverse cardiac event (MACE) rate in moderate-risk patients and how it differs based on history of coronary artery disease (CAD).
METHODS: A secondary analysis of the HEART Pathway implementation study was conducted. This prospective interrupted time-series study accrued adults with possible ACS from three sites (November 2013-January 2016). This analysis excluded low-risk patients determined by emergency providers' HEART Pathway assessments. Non-low-risk patients were further classified as high risk, based on elevated troponin measures or ischemic ECG findings or as moderate risk, based on HEAR score ≥ 4, negative troponin measures, and a nonischemic ECG. Moderate-risk patients were then stratified by the presence or absence of prior CAD (MI, revascularization, or ≥70% coronary stenosis). MACE (death, myocardial infarction, or revascularization) at 30 days was determined from health records, insurance claims, and death index data. MACE rates were compared among groups using a chi-square test and likelihood ratios (LRs) were calculated.
RESULTS: Among 4,550 patients with HEART Pathway assessments, 24.8% (1,130/4,550) were high risk and 37.7% (1715/4550) were moderate risk. MACE at 30 days occurred in 3.1% (53/1,715; 95% confidence interval [CI] = 2.3% to 4.0%) of moderate-risk patients. Among moderate-risk patients, MACE occurred in 7.1% (36/508, 95% CI = 5.1% to 9.8%) of patients with known CAD versus 1.4% (17/1,207, 95% CI = 0.9% to 2.3%) in patients without known prior CAD (p < 0.0001). The negative LR for 30-day MACE among moderate-risk patients without prior CAD was 0.08 (95% CI = 0.05 to 0.12).
CONCLUSION: MACE rates at 30 days were low among moderate-risk patients but were significantly higher among those with prior CAD.
参考来源
- McGinnis HD, Ashburn NP, Paradee BE, et al. Major adverse cardiac event rates in moderate-risk patients: Does prior coronary disease matter? Acad Emerg Med. 2022. PMID: 35166427. doi:10.1111/acem.14462
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。